

Pertuzumab, trastuzumab, and  
hyaluronidase-zzxf (Phesgo™)

Place of Service  
Office Administration  
Infusion Center Administration  
Home Infusion Administration  
Outpatient Facility Administration

HCPCS: J9316 per 10 mg

Condition(s) listed in policy (see criteria for details)

- [Breast cancer \(HER2-positive\)](#)

**AHFS therapeutic class:** Antineoplastic Agent

**Mechanism of action:** combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase

**(1) Special Instructions and Pertinent Information**

**Covered under the Medical Benefit,** please submit clinical information for prior authorization review.

**(2) Prior Authorization/Medical Review is required for the following condition(s)**

All requests for Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

**Breast cancer (HER2-positive)**

1. HER2-positivity, **AND**
2. One of the following:
  - a. Being used for neoadjuvant or adjuvant therapy, **OR**
  - b. For recurrent unresectable or metastatic disease, and meets one of the following:
    - i. For first-line treatment and Patient has not received prior anti-HER2 therapy (e.g.; trastuzumab, pertuzumab, or lapatinib) or chemotherapy for metastatic disease, and will be using Phesgo in combination with docetaxel or paclitaxel, **OR**
    - ii. For subsequent treatment and Patient has received trastuzumab but not Perjeta, and will be using Phesgo with or without chemotherapy

**Covered Doses**

Up to 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase SC on Day 1, followed every 3 weeks by a dose of up to 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase SC

**Coverage Period**

Neoadjuvant/adjuvant:

Cover maximum of 18 doses (1 year)

Recurrent or metastatic:

Cover indefinitely

**ICD-10:**

C50.011, C50.012, C50.019, C50.021, C50.022, C50.029, C50.111, C50.112, C50.119, C50.121, C50.122, C50.129, C50.211, C50.212, C50.219, C50.221, C50.222, C50.229, C50.311, C50.312, C50.319, C50.321, C50.322, C50.329, C50.411, C50.412, C50.419, C50.421, C50.422, C50.429, C50.511, C50.512, C50.519, C50.521, C50.522, C50.529, C50.611, C50.612, C50.619, C50.621, C50.622, C50.629, C50.811, C50.812, C50.819, C50.821, C50.822, C50.829, C50.911, C50.912, C50.919, C50.921, C50.922, C50.929

**(3) The following condition(s) DO NOT require Prior Authorization/Preservice**

All requests for Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

**(4) This Medication is NOT medically necessary for the following condition(s)**

Coverage for a Non-FDA approved indication, requires that criteria outlined in Health and Safety Code § 1367.21, including objective evidence of efficacy and safety are met for the proposed indication.

Please refer to the Provider Manual and User Guide for more information.

**(5) Additional Information**How supplied:

- 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase/15 mL (80 mg, 40 mg, and 2,000 units/mL) of solution in a single-dose vial.
- 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase/10 mL (60 mg, 60 mg, and 2,000 units/mL) of solution in a single-dose vial.

**(6) References**

- AHFS®. Available by subscription at <http://www.lexi.com>
- DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
- National Comprehensive Cancer Network. Breast Cancer (Version 4.2023). Available at <http://www.nccn.org>.
- Phesgo™ (pertuzumab, trastuzumab, hyaluronidase-zzxf) [Prescribing information]. South San Francisco, CA: Genentech Inc/ Roche Group; 6/2020.

**(7) Policy Update**

Date of last review: 3Q2023

Date of next review: 3Q2024

Changes from previous policy version:

- No clinical change to policy following routine annual review.

*BSC Drug Coverage Criteria to Determine Medical Necessity  
Reviewed by P&T Committee*